公开(公告)号：WO0158956A3

公开(公告)日：2002-03-07

申请号：PCT/US0104170

申请日：2001-02-09

Applicant: BASF AG ,  GHAYUR TARIQ ,  DIXON RICHARD W ,  ROGUSKA MIKE ,  WHITE MICHAEL ,  LABKOVSKY BORIS ,  SALFELD JOCHEN ,  DUNCAN ALEXANDER ROBERT ,  BROCKLEHURST SIMON MARK ,  MANKOVICH JOHN ,  SHORROCK CELIA PATRICIA ,  THOMPSON JULIA ELIZABETH ,  LENNARD SIMON NICHOLAS

Inventor： GHAYUR TARIQ ,  DIXON RICHARD W ,  ROGUSKA MIKE ,  WHITE MICHAEL ,  LABKOVSKY BORIS ,  SALFELD JOCHEN ,  DUNCAN ALEXANDER ROBERT ,  BROCKLEHURST SIMON MARK ,  MANKOVICH JOHN ,  SHORROCK CELIA PATRICIA ,  THOMPSON JULIA ELIZABETH ,  LENNARD SIMON NICHOLAS

IPC: C12N15/02 ,  A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  A61K31/445 ,  A61K31/505 ,  A61K31/56 ,  A61K38/13 ,  A61K38/17 ,  A61P1/00 ,  A61P3/00 ,  A61P5/00 ,  A61P9/00 ,  A61P13/00 ,  A61P19/00 ,  A61P21/00 ,  A61P25/00 ,  C12N15/13 ,  C12N15/85

CPC classification number: C07K16/244 ,  A61K31/519 ,  A61K31/56 ,  A61K38/13 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  A61K39/395 ,  A61K31/00

Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo . An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

Abstract translation: 提供了结合人白细胞介素-18（hIL-18）的抗体，特别是结合人IL-18表位的抗体。 抗体可以是例如完全是人抗体，重组抗体或单克隆抗体。 优选的抗体对hIL-18具有高亲和力，并且在体外和体内<！ - SIPO - >中和hIL-18活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-18和抑制hIL-18活性，例如在患有hIL-18活性有害的病症的人类受试者中。

公开(公告)号：NO319955B1

公开(公告)日：2005-10-03

申请号：NO20026202

申请日：2002-12-23

Applicant: BASF AG

Inventor： SALFELD JOCHEN G ,  ALLEN DEBORAH J ,  HOOGENBOOM HENDRICUS R J M ,  KAYMAKCALAN ZEHRA ,  LABKOVSKY BORIS ,  MANKOVICH JOHN A ,  MCGUINNES BRIAN T ,  ROBERTS ANDREW J ,  SAKORAFAS PAUL ,  SCHOENHAUT DAVID ,  VAUGHAN TRISTAN J ,  WHITE MICHAEL ,  WILTON ALISON JANE

IPC: C12N15/09 ,  A61K31/00 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/505 ,  A61K31/517 ,  A61K31/52 ,  A61K31/529 ,  A61K31/57 ,  A61K31/573 ,  A61K31/675 ,  A61K38/00 ,  A61K38/04 ,  A61K38/16 ,  A61K39/39 ,  A61K39/395 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/04 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P11/00 ,  A61P11/16 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P27/02 ,  A61P29/02 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P33/06 ,  A61P35/00 ,  A61P35/04 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/02 ,  C07K16/24 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  G01N33/53 ,  G01N33/543 ,  G01N33/564 ,  G01N33/576 ,  G01N33/68

Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

公开(公告)号：AT239041T

公开(公告)日：2003-05-15

申请号：AT97906572

申请日：1997-02-10

Applicant: BASF AG

Inventor： SALFELD JOCHEN G ,  ALLEN DEBORAH J ,  KAYMAKCALAN ZEHRA ,  LABKOVSKY BORIS ,  MANKOVICH JOHN A ,  MCGUINESS BRIAN T ,  ROBERTS ANDREW J ,  SAKORAFAS PAUL ,  HOOGENBOOM HENDRICUS R J M ,  SCHOENHAUT DAVID ,  VAUGHAN TRISTAN J ,  WHITE MICHAEL ,  WILTON ALISON J

IPC: C12N15/09 ,  A61K31/00 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/505 ,  A61K31/517 ,  A61K31/52 ,  A61K31/529 ,  A61K31/57 ,  A61K31/573 ,  A61K31/675 ,  A61K38/00 ,  A61K38/04 ,  A61K38/16 ,  A61K39/39 ,  A61K39/395 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/04 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P11/00 ,  A61P11/16 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P27/02 ,  A61P29/02 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P33/06 ,  A61P35/00 ,  A61P35/04 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/02 ,  C07K16/24 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  G01N33/53 ,  G01N33/543 ,  G01N33/564 ,  G01N33/576 ,  G01N33/68 ,  C12N15/13 ,  C12N15/64

Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

公开(公告)号：CA2243459C

公开(公告)日：2002-09-17

申请号：CA2243459

申请日：1997-02-10

Applicant: BASF AG

Inventor： VAUGHAN TRISTAN J ,  ALLEN DEBORAH J ,  SALFELD JOCHEN G ,  WHITE MICHAEL ,  HOOGENBOOM HENDRICUS R J M ,  MANKOVICH JOHN A ,  MCGUINNESS BRIAN T ,  KAYMAKCALAN ZEHRA ,  ROBERTS ANDREW J ,  SAKORAFAS PAUL ,  SCHOENHAUT DAVID ,  WILTON ALISON J ,  LABKOVSKY BORIS

IPC: C12N15/09 ,  A61K31/00 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/505 ,  A61K31/517 ,  A61K31/52 ,  A61K31/529 ,  A61K31/57 ,  A61K31/573 ,  A61K31/675 ,  A61K38/00 ,  A61K38/04 ,  A61K38/16 ,  A61K39/39 ,  A61K39/395 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/04 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P11/00 ,  A61P11/16 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P27/02 ,  A61P29/02 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P33/06 ,  A61P35/00 ,  A61P35/04 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/02 ,  C07K16/24 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  G01N33/53 ,  G01N33/543 ,  G01N33/564 ,  G01N33/576 ,  G01N33/68 ,  C12N15/13

Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor .alpha. (hTNF.alpha.) are disclosed. The se antibodies have high affinity for hTNF.alpha.(e.g., Kd = 10-8 M or less), a slow off rate for hTNF.alpha. dissociation (e.g., Koff = 10-3sec-1 or less) and neutralize hTNF.alpha. activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereo f. The antibodies, or antibody portions, of the invention are useful for detecting hTNF.alpha. and for inhibiting hTNF.alpha. activity, e.g., in a human subject suffering from a disorder in which hTNF.alpha. activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing t he recombinant human antibodies, are also encompassed by the invention.

公开(公告)号：TR199801532T2

公开(公告)日：1998-11-23

申请号：TR9801532

申请日：1997-02-10

Applicant: BASF AG

Inventor： SALFELD JACHEN G ,  ALLEN DEBORAH J ,  KAYMAKCALAN ZEHRA ,  LABKOVSKY BORIS ,  MANKOVICH JOHN A ,  MACGUINESS BRIAN T ,  ROBERTS ANDREW J ,  SAKORAFAS PAUL ,  HOOGENBOOM HENDRICUS R J M ,  SCHOENHAUT DAVID ,  VAUGHAN TRISTAN J ,  WHITE MICHAEL ,  WILTON ALISON J

IPC: C12N15/09 ,  A61K31/00 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/505 ,  A61K31/517 ,  A61K31/52 ,  A61K31/529 ,  A61K31/57 ,  A61K31/573 ,  A61K31/675 ,  A61K38/00 ,  A61K38/04 ,  A61K38/16 ,  A61K39/39 ,  A61K39/395 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/04 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P11/00 ,  A61P11/16 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P27/02 ,  A61P29/02 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P33/06 ,  A61P35/00 ,  A61P35/04 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/02 ,  C07K16/24 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  G01N33/53 ,  G01N33/543 ,  G01N33/564 ,  G01N33/576 ,  G01N33/68

Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

公开(公告)号：CZ9802476A3

公开(公告)日：1998-11-11

申请号：CZ247698

申请日：1997-02-10

Applicant: BASF AG

Inventor： SALFELD JOCHEN G ,  ALLEN DEBORA J ,  KAYMAKCALAN ZEHRA ,  LABKOVSKY BORIS ,  MANKOVICH JOHN A ,  MCGUINESS BRIAN T ,  ROBERTS ANDREW J ,  SAKORAFAS PAUL ,  HOOGENBOOM HENDRICUS R J M ,  SCHOENHAUT DAVID ,  VAUGHAN TRISTAN J ,  WHITE MICHAEL ,  WILTON ALISON J

IPC: C12N15/09 ,  A61K31/00 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/505 ,  A61K31/517 ,  A61K31/52 ,  A61K31/529 ,  A61K31/57 ,  A61K31/573 ,  A61K31/675 ,  A61K38/00 ,  A61K38/04 ,  A61K38/16 ,  A61K39/39 ,  A61K39/395 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/04 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P11/00 ,  A61P11/16 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P27/02 ,  A61P29/02 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P33/06 ,  A61P35/00 ,  A61P35/04 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/02 ,  C07K16/24 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  G01N33/53 ,  G01N33/543 ,  G01N33/564 ,  G01N33/576 ,  G01N33/68 ,  C12N15/13 ,  C12N15/64

CPC classification number: C07K16/241 ,  A61K38/00 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  Y02A50/412 ,  Y10S424/81

Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor alpha(hTNFalpha) are disclosed. These antibodies have high affinity for hTNFalpha (e.g., Kd=10-8 M or less), a slow off rate for hTNFalpha dissociation (e.g., Koff=10-3sec-1 or less) and neutralize hTNFalpha activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFalpha and for inhibiting hTNFalpha activity, e.g., in a human subject suffering from a disorder in which hTNFalpha activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

公开(公告)号：NO20026202L

公开(公告)日：1998-10-07

申请号：NO20026202

申请日：2002-12-23

Applicant: BASF AG

Inventor： SALFELD JOCHEN G ,  ALLEN DEBORAH J ,  HOOGENBOOM HENDRICUS R J M ,  KAYMAKCALAN ZEHRA ,  LABKOVSKY BORIS ,  MANKOVICH JOHN A ,  MCGUINNES BRIAN T ,  ROBERTS ANDREW J ,  SAKORAFAS PAUL ,  SCHOENHAUT DAVID ,  VAUGHAN TRISTAN J ,  WHITE MICHAEL ,  WILTON ALISON JANE

IPC: C12N15/09 ,  A61K31/00 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/505 ,  A61K31/517 ,  A61K31/52 ,  A61K31/529 ,  A61K31/57 ,  A61K31/573 ,  A61K31/675 ,  A61K38/00 ,  A61K38/04 ,  A61K38/16 ,  A61K39/39 ,  A61K39/395 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/04 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P11/00 ,  A61P11/16 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P27/02 ,  A61P29/02 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P33/06 ,  A61P35/00 ,  A61P35/04 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/02 ,  C07K16/24 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  G01N33/53 ,  G01N33/543 ,  G01N33/564 ,  G01N33/576 ,  G01N33/68

Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

公开(公告)号：CA2243459A1

公开(公告)日：1997-08-14

申请号：CA2243459

申请日：1997-02-10

Applicant: BASF AG

Inventor： WILTON ALISON J ,  KAYMAKCALAN ZEHRA ,  LABKOVSKY BORIS ,  MANKOVICH JOHN A ,  SCHOENHAUT DAVID ,  ALLEN DEBORAH J ,  HOOGENBOOM HENDRICUS R J M ,  MCGUINESS BRIAN T ,  ROBERTS ANDREW J ,  WHITE MICHAEL ,  SAKORAFAS PAUL ,  SALFELD JOCHEN G ,  VAUGHAN TRISTAN J

IPC: C12N15/09 ,  A61K31/00 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/505 ,  A61K31/517 ,  A61K31/52 ,  A61K31/529 ,  A61K31/57 ,  A61K31/573 ,  A61K31/675 ,  A61K38/00 ,  A61K38/04 ,  A61K38/16 ,  A61K39/39 ,  A61K39/395 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/04 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P11/00 ,  A61P11/16 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P27/02 ,  A61P29/02 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P33/06 ,  A61P35/00 ,  A61P35/04 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/02 ,  C07K16/24 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  G01N33/53 ,  G01N33/543 ,  G01N33/564 ,  G01N33/576 ,  G01N33/68 ,  C12N15/13

Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor .alpha. (hTNF.alpha.) are disclosed. The se antibodies have high affinity for hTNF.alpha.(e.g., Kd = 10-8 M or less), a slow off rate for hTNF.alpha. dissociation (e.g., Koff = 10-3sec-1 or less) and neutralize hTNF.alpha. activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereo f. The antibodies, or antibody portions, of the invention are useful for detecting hTNF.alpha. and for inhibiting hTNF.alpha. activity, e.g., in a human subject suffering from a disorder in which hTNF.alpha. activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing t he recombinant human antibodies, are also encompassed by the invention.

公开(公告)号：CA2389943C

公开(公告)日：2009-04-07

申请号：CA2389943

申请日：1997-02-10

Applicant: BASF AG

Inventor： WHITE MICHAEL ,  VAUGHAN TRISTAN J ,  WILTON ALISON J ,  KAYMAKCALAN ZEHRA ,  HOOGENBOOM HENDRICUS R J M ,  ALLEN DEBORAH J ,  SCHOENHAUT DAVID ,  LABKOVSKY BORIS ,  SAKORAFAS PAUL ,  SALFELD JOCHEN G ,  MCGUINNESS BRIAN T ,  ROBERTS ANDREW J ,  MANKOVICH JOHN A

IPC: C12N15/09 ,  C12N15/13 ,  A61K31/00 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/505 ,  A61K31/517 ,  A61K31/52 ,  A61K31/529 ,  A61K31/57 ,  A61K31/573 ,  A61K31/675 ,  A61K38/00 ,  A61K38/04 ,  A61K38/16 ,  A61K39/39 ,  A61K39/395 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/04 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P11/00 ,  A61P11/16 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P27/02 ,  A61P29/02 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P33/06 ,  A61P35/00 ,  A61P35/04 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/02 ,  C07K16/24 ,  C12N1/21 ,  C12N5/10 ,  C12N15/28 ,  C12N15/63 ,  C12N15/64 ,  C12P21/08 ,  G01N33/53 ,  G01N33/543 ,  G01N33/564 ,  G01N33/576 ,  G01N33/68

Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor .alpha. (hTNF.alpha.) are disclosed. These antibodies have high affinity for hTNF.alpha. (e.g., K d = 10 -8 M or less), a slow off rate for hTNF.alpha. dissociation (e.g., K off = 10 -3sec-1 or less) and neutralize hTNF.alpha. activity in vitro and in vivo. An antibody of the invention can be a full--length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF.alpha. and for inhibiting hTNF.alpha. activity, e.g., in a human subject suffering from a disorder in which hTNF.alpha. activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

公开(公告)号：NO322755B1

公开(公告)日：2006-12-04

申请号：NO20040052

申请日：2004-01-07

Applicant: BASF AG

Inventor： SALFELD JOCHEN G ,  ALLEN DEBORAH J ,  HOOGENBOOM HENDRICUS R J M ,  KAYMAKCALAN ZEHRA ,  LABKOVSKY BORIS ,  MANKOVICH JOHN A ,  MCGUINNES BRIAN T ,  ROBERTS ANDREW J ,  SAKORAFAS PAUL ,  SCHOENHAUT DAVID ,  VAUGHAN TRISTAN J ,  WHITE MICHAEL ,  WILTON ALISON JANE

IPC: A61K39/395 ,  C12N15/09 ,  A61K31/00 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/505 ,  A61K31/517 ,  A61K31/52 ,  A61K31/529 ,  A61K31/57 ,  A61K31/573 ,  A61K31/675 ,  A61K38/00 ,  A61K38/04 ,  A61K38/16 ,  A61K39/39 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/04 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P11/00 ,  A61P11/16 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P27/02 ,  A61P29/02 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P33/06 ,  A61P35/00 ,  A61P35/04 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/02 ,  C07K16/24 ,  C12N1/21 ,  C12N5/10 ,  C12N15/13 ,  C12P21/08 ,  G01N33/53 ,  G01N33/543 ,  G01N33/564 ,  G01N33/576 ,  G01N33/68

Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.